Subcutaneous infliximab use in children with inflammatory bowel disease in an Australian center
Journal of Pediatric Gastroenterology and Nutrition · 2026
DOI: 10.1002/jpn3.70267 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, 2026. Verfasst von Jessica A Eldredge und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The Children's Hospital at Westmead, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Infliximab, Gastrointestinal Agents, Inflammatory Bowel Diseases, Colitis, Ulcerative. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: None.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Objectives
Experience with subcutaneous infliximab (SC‐IFX) use in pediatric inflammatory bowel disease (IBD) remains limited. We aimed to evaluate the clinical efficacy, tolerability, and cost–benefit of SC‐IFX as a treatment for children with IBD in a real‐world setting.
Methods
A prospective, single‐center cohort study was conducted at the Children's Hospital at Westmead, Australia, from February to June 2024. Thirty‐three children aged 8–18 years with established IBD commenced SC‐IFX (120 mg fortnightly). Assessments included clinical disease activity indices (Pediatric Crohn's Disease Activity Index [PCDAI]/Pediatric Ulcerative Colitis Activity Index [PUCAI]), biochemical markers, and infliximab levels. Patient experience was assessed via questionnaires on quality‐of‐life (QOL) and treatment satisfaction.
Results
Thirty‐one (31/33) children completed treatment over a 12‐week follow‐up period. Median infliximab levels increased from 7.8 ug/mL (interquartile range [IQR]: 5.7–11) at baseline to 19.6 ug/mL (IQR: 13.2–21.8) at Week 12 ( p < 0.001). Serum infliximab level >20 ug/mL was seen in 48% of children at Week 12. Minimal change was observed in fecal calprotectin and clinical disease activity indices. High satisfaction rates with improved patient and caregiver QOL are described. Cost analyses indicated a potential for net institutional savings. Drug continuation was planned in 85% (28/33) following the 12‐week study period.
Conclusions
Our experience suggests SC‐IFX may be an effective and well‐tolerated alternative to intravenous infliximab (IV‐IFX) in pediatric IBD. Median serum infliximab levels increased across over the study period. Use of SC‐IFX may offer a positive impact on patient and caregiver QOL, along with resource and cost saving benefits for healthcare systems. Larger‐scale studies are needed to validate these findings and optimize treatment protocols.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, The Children's Hospital at Westmead, Sydney, New South Wales, Australia.
- Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
- Pharmacy Department, The Children's Hospital at Westmead, Sydney, New South Wales, Australia.
ORCID-Profile: Jessica A Eldredge
Förderung
- None
Zitieren
APA
Eldredge, J. A., Kaur, R., Chua, C. W., Chidgey, T., Tano, M., Singh, N., Barclay, P., Magoffin, A., Thacker, K., Dutt, S., & O'Loughlin, E. V. (2026). Subcutaneous infliximab use in children with inflammatory bowel disease in an Australian center. Journal of Pediatric Gastroenterology and Nutrition. https://doi.org/10.1002/jpn3.70267
Vancouver
Eldredge JA, Kaur R, Chua CW, Chidgey T, Tano M, Singh N, et al. Subcutaneous infliximab use in children with inflammatory bowel disease in an Australian center. Journal of Pediatric Gastroenterology and Nutrition. 2026. doi:10.1002/jpn3.70267
BibTeX
@article{Eldredge2026,
author = {Eldredge, Jessica A and Kaur, Rajneesh and Chua, Cher Wei and Chidgey, Trudy and Tano, Michelle and Singh, Noel and Barclay, Peter and Magoffin, Annabel and Thacker, Kunal and Dutt, Shoma and O'Loughlin, Edward V},
title = {Subcutaneous infliximab use in children with inflammatory bowel disease in an Australian center},
journal = {Journal of Pediatric Gastroenterology and Nutrition},
year = {2026},
doi = {10.1002/jpn3.70267}
}
EUVIMED